Scarica l'app Stockscreener
1.05
17.55%
0.1568
Pre-mercato:
1.09
0.04
+3.81%
Precedente Chiudi:
$0.8932
Aprire:
$0.86
Volume 24 ore:
370.55K
Relative Volume:
2.37
Capitalizzazione di mercato:
$59.43M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-0.5899
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
+15.77%
1M Prestazione:
+30.43%
6M Prestazione:
+16.34%
1 anno Prestazione:
-80.11%
Intervallo 1D:
$0.8525
$1.05
Intervallo di 1 settimana:
$0.82
$1.05
Portata 52W:
$0.6101
$5.945
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Confronta PRLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.05 | 53.44M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Iniziato | Jefferies | Buy |
| 2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-26 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Goldman | Neutral |
| 2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
What makes Prelude Therapeutics Incorporated stock price move sharplyJuly 2025 Volume & Free Community Supported Trade Ideas - Newser
Price momentum metrics for Prelude Therapeutics Incorporated explainedJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser
Can swing trading help recover from Prelude Therapeutics Incorporated losses2025 Pullback Review & Pattern Based Trade Signal System - Newser
Quantitative breakdown of Prelude Therapeutics Incorporated recent moveMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
Is now a turning point for Prelude Therapeutics IncorporatedEarnings Recap Summary & AI Enhanced Trading Alerts - Newser
Analyzing drawdowns of Prelude Therapeutics Incorporated with statistical tools2025 Technical Overview & Growth Focused Stock Reports - Newser
Prelude Therapeutics Incorporated recovery potential after sell off2025 Breakouts & Breakdowns & Technical Confirmation Alerts - Newser
Chart overlay techniques for tracking Prelude Therapeutics IncorporatedJuly 2025 Earnings & Long Hold Capital Preservation Tips - Newser
Prelude Therapeutics (NASDAQ:PRLD) Given New $3.00 Price Target at JMP Securities - Defense World
Tick level data insight on Prelude Therapeutics Incorporated volatilityWeekly Trade Analysis & Weekly High Conviction Ideas - Newser
Prelude Therapeutics (NASDAQ:PRLD) Trading Up 8.5% – Here’s What Happened - Defense World
Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMP - TipRanks
Will Prelude Therapeutics Incorporated stock go up soon2025 Dividend Review & Community Consensus Trade Alerts - Newser
Has Prelude Therapeutics Incorporated found a price floor2025 AllTime Highs & Safe Entry Point Alerts - Newser
Risk vs reward if holding onto Prelude Therapeutics IncorporatedTrade Exit Summary & Daily Growth Stock Tips - Newser
How to build a dashboard for Prelude Therapeutics Incorporated stockJuly 2025 Market Mood & Target Return Focused Picks - Newser
Prelude Therapeutics Refocuses SMARCA2 Program, Cuts Quarterly Losses - MyChesCo
Best data tools to analyze Prelude Therapeutics Incorporated stockMarket Performance Summary & Advanced Technical Analysis Signals - Newser
Will Prelude Therapeutics Incorporated bounce back from current supportQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - Newser
Is Prelude Therapeutics Incorporated reversing from oversold territoryNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Does Prelude Therapeutics Incorporated qualify in momentum factor screening2025 Valuation Update & Advanced Technical Analysis Signals - Newser
Is it time to cut losses on Prelude Therapeutics IncorporatedJuly 2025 Volume & AI Driven Price Forecasts - Newser
Prelude Therapeutics Incorporated stock trendline breakdown2025 Winners & Losers & Comprehensive Market Scan Insights - Newser
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionQuarterly Profit Report & Real-Time Volume Analysis Alerts - Newser
Is Prelude Therapeutics Incorporated trading at a discountTrade Risk Summary & Community Verified Trade Signals - thegnnews.com
Neurizon cites ‘strain’ at FDA as reason for delay on IND hold; Fifty Years’ $126M fund - Endpoints News
Prelude Therapeutics Reports Q2 2025 Financial Results - TipRanks
Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development - TipRanks
Prelude Cuts Q2 Losses and Costs 13% - The Motley Fool
Prelude (PRLD) Announces Q2 2025 Results; Presentation Attached | PRLD SEC FilingForm 8-K - Stock Titan
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Prelude Therapeutics Inc Azioni (PRLD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
2.44%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):